Home
About
Publications Trends
Recent Publications
Expert Search
Archive
epigenetic drugs
What Types of Epigenetic Drugs Are Currently Available?
Several classes of epigenetic drugs have been developed, including:
DNA methyltransferase inhibitors (DNMTis)
: These drugs prevent the addition of methyl groups to DNA, thereby reactivating silenced tumor suppressor genes.
Histone deacetylase inhibitors (HDACis)
: These compounds inhibit the deacetylation of histones, leading to a more relaxed chromatin structure and increased gene expression.
Bromodomain and extra-terminal domain inhibitors (BETis)
: These drugs block the interaction between bromodomains and acetylated histones, affecting the expression of oncogenes.
Frequently asked queries:
What Are Epigenetic Drugs?
How Do Epigenetic Modifications Contribute to Cancer?
What Types of Epigenetic Drugs Are Currently Available?
What Are the Clinical Applications of Epigenetic Drugs?
Why is CME Important in Cancer Care?
How is the Rate of Progression Measured?
What Services Do Oncology Units Provide?
How Can Transparency Be Improved?
How Can Cadmium Exposure be Prevented?
Can Reverse Osmosis Remove Carcinogens?
How Do Liquid Biopsy Kits Work?
What are the Signs and Symptoms?
How is the MTT Assay Performed?
Why are Simulation Drills Important?
How Do Nutrition and Diet Play a Role?
What Can Be Done to Mitigate Cross Border Pollution?
Are There Any Costs Involved?
How Do Computational Methods Aid in Drug Discovery?
What is the American Board of Integrative Medicine?
What Role Do Patients Play in EHR Systems?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
epirubicin-cyclophosphamide
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe